Adenosine deaminase deficiency is a rare genetic condition that causes severe problems with the immune system. Many people with Adenosine deaminase deficiency have frequent serious infections and poor growth in infancy, and some have breathing or feeding troubles. It is lifelong, but early treatment can restore immune function and improve survival. Treatment often includes enzyme replacement, stem cell transplant, or gene therapy, along with infection prevention. The outlook varies by how early care starts and by access to therapy, and many people live longer, healthier lives with modern treatment.
Overview
Adenosine deaminase deficiencySymptoms
Early signs of adenosine deaminase deficiency often appear in infancy: severe, repeated infections, poor weight gain, chronic diarrhea, and persistent thrush. Babies may have pneumonia and few or small tonsils or lymph nodes. Later-onset cases bring frequent infections and fatigue.
Outlook and prognosis
Many people with adenosine deaminase deficiency do well long term with timely, specialized care. Early treatment—enzyme replacement, stem cell transplantation, or gene therapy—can restore immune function and lower serious infection risk. Ongoing follow-up supports growth, development, and daily life.
Causes and risk factors
Adenosine deaminase deficiency comes from ADA gene mutations, usually inherited autosomal recessively from two carrier parents. Risk factors for adenosine deaminase deficiency include family history and parental consanguinity; environment or lifestyle don’t cause it but may influence severity.
Genetic influences
Genetics are central in adenosine deaminase deficiency. Most cases result from inherited variants in the ADA gene, passed in an autosomal recessive pattern. Specific variants can influence how early symptoms of adenosine deaminase deficiency appear and how severe they are.
Diagnosis
Doctors suspect it from recurrent severe infections, poor growth, and very low lymphocytes. Blood tests show absent ADA enzyme activity; newborn screening may flag SCID. Genetic diagnosis of Adenosine deaminase deficiency confirms ADA gene variants.
Treatment and drugs
Treatment for adenosine deaminase (ADA) deficiency focuses on restoring the missing enzyme and protecting the immune system. Options include enzyme replacement therapy, stem cell (bone marrow) transplant, and in select cases gene therapy, plus prompt infection prevention and routine immunology follow-up.
Symptoms
Frequent infections, slow growth, and stubborn thrush can be early clues that the immune system isn’t working as it should. The early features of Adenosine deaminase deficiency often begin in the first months of life and can be severe. Early on, this might look like colds that don’t clear, cough that lingers, or feeds that take a long time without much weight gain. Doctors may also notice fewer or smaller lymph nodes and other signs that the body isn’t mounting a typical immune response.
Frequent ear, sinus, and lung infections are common. They can last longer, come back quickly, or not respond well to standard antibiotics. In Adenosine deaminase deficiency, this pattern often starts in early infancy.
Infections may be more serious than expected. Germs that rarely cause illness in others can lead to pneumonia or serious blood infections. This can happen in Adenosine deaminase deficiency because the immune system lacks key defenses.
Babies may gain weight slowly or fall off their growth curve. Feeding can take a long time without much progress. Poor growth is common in Adenosine deaminase deficiency when infections are frequent.
Loose stools can be ongoing. This can lead to dehydration and poor nutrient absorption. Diarrhea may flare with each new infection.
How people usually first notice Adenosine deaminase deficiency?
Many families first notice adenosine deaminase (ADA) deficiency when a newborn or infant has frequent, severe infections that don’t clear as expected, poor weight gain, or persistent thrush. Doctors often pick it up through newborn screening in some regions, or after blood tests show very low lymphocyte counts—pointing to severe combined immunodeficiency (SCID). In pregnancies, it may rarely be suspected after a prior affected child or through targeted prenatal genetic testing, but for most, the first signs of ADA deficiency appear in early infancy as serious, recurrent infections.
Types of Adenosine deaminase deficiency
Adenosine deaminase deficiency is a genetic condition with a few well-recognized clinical variants that affect how early symptoms appear and how severe they are. These variants relate to how much enzyme activity remains, which can range from almost none to partially reduced. People may notice different sets of symptoms depending on their situation, but the core issue is immune system weakness that can be profound in infancy or milder later on. If you’re reading about types of ADA deficiency, you’ll often see them grouped by age at onset and severity.
Severe infantile-onset
Symptoms begin in the first months of life with frequent serious infections and poor growth. Doctors often find very low lymphocyte counts and a near-absent immune response. Without treatment, infections can become life‑threatening early on.
Intermediate childhood-onset
Symptoms appear later in childhood with recurrent ear, sinus, or lung infections and slow growth or fatigue. Lab tests show reduced, but not absent, immune cells and enzyme activity. Learning or hearing differences may be noted in some children.
Late-onset milder
Symptoms surface in adolescence or adulthood, often as repeated respiratory infections and low stamina. Immune weakness is present but usually less severe than early forms. Some people are diagnosed only after family screening or unusual infection patterns.
Partial ADA deficiency
A hypomorphic or “leaky” variant leaves measurable enzyme activity. People may have few infections in early life but develop problems under stress, during pregnancy, or with certain exposures. Monitoring helps guide if and when treatment is needed.
Post‑therapy immune course
After enzyme replacement, gene therapy, or transplant, the immune system can recover to different degrees. Some people reach near‑normal function while others have partial improvement. The balance of symptoms can shift over time.
What genetics can tell you about symptoms
Some genetic changes in the ADA gene leave the enzyme barely working, leading to severe combined immunodeficiency in infants with frequent infections, poor growth, and chronic diarrhea. Milder variants can cause later-onset immune problems, recurrent ear or sinus infections, and breathing issues.
Causes and risk factors
Adenosine deaminase deficiency happens when harmful changes affect both copies of the ADA gene and the ADA enzyme stops working well. It is inherited in an autosomal recessive way, and each parent is usually a healthy carrier. Risk factors for adenosine deaminase deficiency include having carrier parents, a sibling with the condition, or parents who are related by blood. Severity is shaped by biology and often depends on how much ADA enzyme activity remains in the body. Genes set the stage, but environment and lifestyle often decide how the story unfolds.
Environmental and biological risk factors
Here’s what we know about environmental and biological risk factors that influence how adenosine deaminase (ADA) deficiency arises. Doctors often group risks into internal (biological) and external (environmental). For this condition, evidence points mainly to internal, body-based factors set very early in development. Research has not shown clear environmental drivers for most risk factors for ADA deficiency.
In most cases, the chance of this condition is set at the earliest stages of embryo development. These factors are established before birth rather than shaped by events later in pregnancy.
No specific environmental exposure has been shown to raise the likelihood of this condition. Typical variations in air quality, household products, or workplace settings have not been linked to higher risk.
With increasing paternal age, random changes can occur more often in reproductive cells. This could very rarely contribute to a new case of ADA deficiency even without a family history. The absolute chance remains very low.
Common maternal health issues during pregnancy have not been shown to increase the chance of this condition. Complications like high blood pressure or infections may affect pregnancy in other ways, but links to this risk are not supported by evidence.
Genetic risk factors
Variants in the ADA gene drive the risk for adenosine deaminase (ADA) deficiency by reducing or stopping the enzyme’s function. Some risk factors are inherited through our genes. The condition follows an autosomal recessive pattern, meaning a child usually needs two nonworking copies—one from each parent—to develop ADA deficiency. How severe it is often depends on how much enzyme activity remains.
ADA gene changes: Changes (variants) in the ADA gene disrupt the enzyme that helps clear a natural chemical byproduct. Many different variants exist, and their effects can range from mild to severe.
Autosomal recessive: Developing ADA deficiency usually requires two nonworking copies of the ADA gene, one from each parent. With only one changed copy, most people are healthy carriers without symptoms.
Carrier parents: If both parents carry an ADA variant, each pregnancy has a 25% chance of a child with ADA deficiency. There is also a 50% chance the child will be a healthy carrier and a 25% chance of inheriting no variant.
Family history: Having a sibling or close relative with ADA deficiency increases the chance you carry the same variant. When a family variant is known, targeted testing can clarify risks for future pregnancies or newborns.
Parental relatedness: Parents who are related by blood are more likely to share the same rare ADA variant. This raises the likelihood their child will inherit two nonworking copies.
Residual activity level: The specific variants you inherit determine how much ADA enzyme activity remains, which influences severity and age at onset. Early symptoms of adenosine deaminase deficiency are more likely when activity is extremely low. Variants that leave some activity may lead to later or milder features.
Lifestyle risk factors
Adenosine deaminase deficiency is a genetic condition; lifestyle habits do not cause it. However, daily choices can meaningfully influence infection risk, treatment success, and overall health in this immune disorder. Understanding how lifestyle affects Adenosine deaminase deficiency can help reduce complications and support therapies. The elements below focus on behaviors that directly impact infection rates, resilience, and recovery.
Frequent handwashing and avoiding close contact with people who are ill can reduce respiratory and gastrointestinal infections in ADA deficiency. Fewer infections mean fewer hospitalizations and less damage to the lungs and airways.
Avoid raw or undercooked meats, eggs, and unpasteurized products to lower foodborne infection risk in severe immunodeficiency. Careful food handling and prompt refrigeration help prevent prolonged diarrheal illness and weight loss.
Eating enough calories, protein, and micronutrients supports growth and immune recovery in ADA deficiency. Malnutrition can worsen infection severity and slow response to enzyme therapy or transplant recovery.
Gentle, regular movement can maintain lung capacity and reduce deconditioning in ADA deficiency. Scale back and rest during fevers or active infections to avoid complications.
Risk prevention
Adenosine deaminase deficiency is inherited, so the condition itself can’t be prevented after conception, but families can lower the chance of having an affected child through genetic planning. For people living with ADA deficiency, prevention focuses on avoiding infections, catching problems early, and starting treatments that restore immune function as soon as possible. Knowing your risks can guide which preventive steps matter most. Close follow-up with a specialist team helps tailor these steps over time as needs change.
If ADA deficiency runs in your family or you and your partner are from a high‑risk group, consider carrier testing. A genetics professional can explain chances for future children and options like partner testing, prenatal testing, or IVF with embryo testing.
Many regions screen newborns for severe immune problems so treatment can start quickly. Because early symptoms of adenosine deaminase deficiency often appear in the first months of life, prompt diagnosis can reduce infections and complications.
Starting enzyme replacement therapy or considering a stem cell transplant early can rebuild immune defense. Earlier treatment lowers the time spent with severe immune weakness and helps prevent serious infections.
Careful handwashing, avoiding sick contacts, and limiting crowded indoor spaces reduce exposure to germs. During community outbreaks, masks and distancing may add protection.
Transmission
Adenosine deaminase deficiency is a genetic condition; it isn’t contagious and can’t be spread through contact, coughs, or blood. Most often, a child is affected when they inherit two nonworking copies of the ADA gene—one from each parent—an autosomal recessive pattern. If both parents are carriers, each pregnancy has a 25% (1 in 4) chance of adenosine deaminase deficiency, a 50% (1 in 2) chance of a carrier child, and a 25% (1 in 4) chance of an unaffected, noncarrier child. Rarely, a new gene change can cause ADA deficiency even without a known family history; carrier screening and genetic counseling can help explain how adenosine deaminase deficiency is inherited.
When to test your genes
Because adenosine deaminase (ADA) deficiency is inherited, consider genetic testing if there’s a family history, an infant with severe or recurrent infections, or unexplained low lymphocytes. Test before having children to clarify carrier status and options. If diagnosed, testing guides enzyme replacement, gene therapy eligibility, and infection-prevention plans.
Diagnosis
Adenosine deaminase deficiency is usually picked up because of frequent, severe infections in infancy or early childhood and trouble gaining weight. For many, the first step comes when everyday activities start feeling harder, like constant colds that don’t clear or hospital stays for infections most kids fight off at home. Early and accurate diagnosis can help you plan ahead with confidence. Doctors then use a mix of lab tests and genetic testing to confirm the cause and guide urgent treatment decisions.
Recurrent or severe infections, persistent thrush, and poor growth raise early concern for a serious immune problem. These patterns help point toward severe combined immune deficiency (SCID), which includes ADA deficiency.
Blood tests measure lymphocytes and their subtypes (T, B, and NK cells). Very low T cells with low or variable B and NK cells support SCID and can fit ADA deficiency.
Total IgG, IgA, and IgM are often reduced. Low levels suggest the immune system cannot make effective antibodies and support a SCID picture.
A specialized test measures ADA activity in blood cells. Markedly low or absent activity is a key marker for ADA deficiency.
Stages of Adenosine deaminase deficiency
Adenosine deaminase deficiency does not have defined progression stages. This condition varies with how much enzyme activity someone has—some babies develop severe immune problems within the first months, while others have milder, later-onset symptoms—so it doesn’t follow a predictable step-by-step course. Doctors diagnose it by piecing together the pattern of frequent or unusual infections, blood tests of immune cells, measuring ADA enzyme activity, and confirming changes in the ADA gene; early symptoms of adenosine deaminase deficiency may also be flagged by some newborn screening programs. Different tests may be suggested to help confirm the cause and guide next steps.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with adenosine deaminase deficiency, the outlook depends on how early the condition is recognized and how quickly the immune system is supported. Without treatment, infants can develop severe infections and breathing problems early on; this is why early symptoms of adenosine deaminase deficiency—like frequent infections, poor weight gain, or chronic coughing—warrant urgent care. With modern therapies, survival and quality of life have improved greatly.
Prognosis refers to how a condition tends to change or stabilize over time. Enzyme replacement given regularly can reduce infections and help growth, though it doesn’t fully restore immune function and usually requires lifelong dosing. Stem cell (bone marrow) transplant can offer a long-term fix when a well-matched donor is available, with many children achieving strong, durable immune recovery and a low risk of severe infections. Gene therapy is an option in some regions; many living with adenosine deaminase deficiency who receive it rebuild immune defenses and can come off enzyme replacement, though long-term follow-up is important.
Mortality is highest in untreated infants due to overwhelming infections, but with timely treatment—especially transplant or gene therapy—survival rates are high and many children attend school, play sports, and keep up with peers. Adults with adenosine deaminase deficiency who were treated in childhood may still need monitoring for lung function, hearing, liver health, and fertility, as well as vaccine planning and infection prevention. Everyone’s journey looks a little different. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Adenosine deaminase deficiency is a rare, inherited immune disorder where outlook depends on how early it’s recognized and which treatment is used. Long-term effects vary widely, and they can involve both the immune system and other parts of the body. While early symptoms of adenosine deaminase deficiency often involve serious infections in infancy, later effects may reflect damage from infections and the condition itself. Many who receive timely, effective treatment now live into adulthood, though some long-term issues can persist.
Without treatment, severe forms are life-threatening in infancy. With modern therapies, long-term survival into adulthood is common. Ongoing health varies by individual.
Even after treatment, some people have a weaker immune response. This can mean repeated sinus, ear, or chest infections over the years. Doctors may track these changes over years to see how the immune system adapts.
Repeated chest infections can leave scarring and widened airways (bronchiectasis). This can cause a lingering cough and shortness of breath with activity. Lung function may stabilize or slowly decline depending on infection control.
In childhood, poor weight gain and shorter height can follow frequent illness and malabsorption. Catch-up growth may occur after effective treatment. Some adults remain smaller than peers.
How is it to live with Adenosine deaminase deficiency?
Living with adenosine deaminase (ADA) deficiency often means navigating frequent or severe infections, hospital visits, and careful infection prevention because the immune system can’t mount a strong defense. Daily life may include protective steps like avoiding crowded spaces during outbreaks, staying on top of vaccines advised by an immunology team, and keeping a consistent schedule for treatments such as enzyme replacement, immunoglobulin infusions, or care after stem cell or gene therapy. For many families, this brings extra planning around school, childcare, and travel, and it can be emotionally taxing for siblings and caregivers who balance vigilance with helping a child live as normally as possible. With coordinated specialty care, emergency plans, and community support, many find a steady rhythm that protects health while making room for play, learning, and connection.
Treatment and drugs
Treatment for adenosine deaminase (ADA) deficiency focuses on restoring the missing enzyme and protecting the immune system from infections. Options include regular enzyme replacement therapy (giving ADA by injection), stem cell transplant from a matched donor to rebuild immune function, and—in selected cases—gene therapy that adds a working ADA gene to a person’s own stem cells. Doctors also use supportive measures such as prompt antibiotics for infections, immune globulin infusions, and careful vaccination planning to lower risk while the immune system recovers. Not every treatment works the same way for every person, so specialists weigh factors like age, severity, infection history, donor availability, and access to gene therapy to tailor a plan. Ask your doctor about the best starting point for you.
Non-drug treatment
Adenosine deaminase deficiency affects the immune system, making infections more likely and severe. Beyond prescriptions, supportive therapies can reduce exposure to germs, strengthen day-to-day health, and prepare you for definitive care. Non-drug care focuses on protection, nutrition, development, and procedures like stem cell transplant or gene therapy when appropriate.
A stem cell transplant, medically known as hematopoietic stem cell transplantation, can rebuild the immune system. It uses healthy donor cells to replace the cells that aren’t working properly.
Gene therapy aims to place a working ADA gene into your own cells. This can help restore immune function without needing a donor.
Limiting exposure to crowds and sick contacts lowers infection risk. Using good ventilation and, when advised, HEPA filtration can add another layer of protection.
Frequent handwashing, cleaning high-touch surfaces, and safe food and water practices help prevent germs from spreading. Keep a plan for quick medical evaluation if a fever or new cough appears.
Your genes may have an impact on how drugs work for you
Medicines for adenosine deaminase (ADA) deficiency can work differently depending on your genes, which influence how well enzyme replacement, gene therapy, or supportive drugs are processed and tolerated. Pharmacogenetic testing may guide dosing and choice, helping reduce side effects and improve benefit.
Pharmacological treatments
Medicines for adenosine deaminase deficiency focus on replacing the missing enzyme, preventing infections, and supporting the immune system. Sometimes medicines are taken short-term (acute treatment), while others are used long-term (maintenance therapy). The main disease-directed drug is pegylated ADA given by injection; other drugs reduce the risk of bacterial, fungal, and viral infections. These treatments help stabilize health while curative options are arranged, especially if early symptoms of adenosine deaminase deficiency led to a new diagnosis.
Elapegademase-lvlr (Revcovi) is injected under the skin to replace ADA activity and clear toxic metabolites; pegademase bovine (Adagen) is an older option still referenced in some settings. Injections are typically given 1–2 times per week, with dose adjusted to labs and clinical response.
Immune globulin (IVIG or SCIG) supplies protective antibodies to lower infection risk. It’s usually given every 3–4 weeks by vein or weekly by skin, and continued until the immune system is strong enough.
Trimethoprim–sulfamethoxazole is used to prevent Pneumocystis pneumonia. If sulfa drugs aren’t tolerated, alternatives include atovaquone, dapsone, or inhaled pentamidine.
Fluconazole or itraconazole may be prescribed to prevent Candida and other fungal infections. Doctors often monitor liver enzymes and potential drug interactions during therapy.
Genetic influences
In most families, adenosine deaminase (ADA) deficiency happens because a change in the ADA gene is inherited from both parents. The ADA enzyme helps break down certain natural chemicals; when it’s missing or low, toxic byproducts build up and harm infection-fighting white blood cells. This is usually passed down in a recessive way—each parent is healthy but carries one nonworking copy, and each pregnancy has a 1 in 4 (25%) chance of a child with ADA deficiency. A “carrier” means you hold the gene change but may not show symptoms. Different gene changes can leave different amounts of enzyme activity, which is why ADA deficiency can range from severe disease appearing in the first months of life to milder, later-onset forms. Genetic testing can confirm the diagnosis, clarify who in the family is a carrier, and inform options for future pregnancies.
Is Adenosine deaminase deficiency genetic?
Genetics are central in adenosine deaminase deficiency. Most cases result from inherited variants in the ADA gene, passed in an autosomal recessive pattern. Specific variants can influence how early symptoms of adenosine deaminase deficiency appear and how severe they are.
Pharmacogenetics—how genetics influence drug effects
The specific ADA gene changes you inherit can signal how severe the enzyme shortage is, which helps your team decide how quickly to start therapy and whether enzyme replacement, stem cell transplant, or gene therapy is the best first step. Enzyme replacement is dosed by weight and by tracking ADA activity in the blood; some people develop antibodies that dampen its effect, which is more about the immune system than drug‑processing genes. Before a transplant or gene therapy, short courses of chemotherapy may be used to prepare the bone marrow, and people break down these medicines at different speeds; Doctors can use your genetic information to help refine dosing in this setting when evidence and local practice support it. The success of modern gene therapy for adenosine deaminase deficiency usually doesn’t depend on the exact ADA variant, because the treatment adds a working copy of the gene to your own stem cells. Among medications used to treat adenosine deaminase deficiency, drugs that block ADA (for example, pentostatin) are generally avoided because they can worsen the underlying enzyme problem and raise toxic byproducts. Genes are only part of the picture; age, organ function, infections, and other medicines also shape how your body handles treatment over time.
Interactions with other conditions
For people with adenosine deaminase deficiency, infections are the main way this condition interacts with other diseases. Common viruses, bacteria, and fungi can cause unusually severe or repeated illnesses, and these infections can lead to long-term problems like chronic lung damage or bronchiectasis, which then make future breathing infections tougher to shake. Early symptoms of adenosine deaminase deficiency may overlap with common viral infections in infancy, which can delay diagnosis and allow complications to build. In countries where live vaccines like BCG (for tuberculosis) or oral rotavirus are used, these vaccines can cause illness in people with ADA deficiency, so doctors usually avoid live vaccines until the immune system is safely restored. Some develop autoimmune issues or, rarely, certain blood cancers after years of immune dysregulation or partial immune recovery, and these added conditions can change how treatment is planned. Talk with your doctor about how your conditions may influence each other.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described babies who struggled to gain weight, had constant chest infections, and didn’t survive early childhood. Families and communities once noticed patterns—several infants in the same family becoming ill with severe infections—long before anyone knew why. These early observations captured the day-to-day reality of what we now understand as adenosine deaminase (ADA) deficiency, a cause of severe combined immunodeficiency.
First described in the medical literature as a distinct form of immune failure in the late 1960s, ADA deficiency was initially understood through striking clinical clues: recurrent infections, chronic diarrhea, and poor growth in very young children. Soon, doctors linked these symptoms to unusually low numbers of infection-fighting white blood cells. From these first observations, researchers connected the dots between missing immune cells and a buildup of certain natural chemicals that are normally cleared by the ADA enzyme.
As medical science evolved, measurements of enzyme activity and the discovery of the ADA gene in the 1980s turned a clinical syndrome into a clearly defined inherited condition. This explained why ADA deficiency often appeared in siblings and why parents without symptoms could have more than one affected child. The genetics also clarified that, although most cases showed up in infancy, some milder forms appeared later in childhood or even adulthood, broadening the picture beyond the earliest, most severe descriptions.
With each decade, treatments mirrored the growing understanding of the condition. In the 1970s and 1980s, bone marrow and later stem cell transplants offered a way to rebuild the immune system. By the 1990s, purified enzyme replacement could temporarily restore the missing ADA function for many. Early gene therapy attempts began around the same time, laying groundwork for modern approaches that insert a working copy of the ADA gene into a person’s own stem cells. In recent decades, knowledge has built on a long tradition of observation, and long-term outcomes have improved as supportive care, infection prevention, and curative therapies advanced.
Despite evolving definitions, the central story of ADA deficiency has stayed consistent: when the ADA enzyme is missing or severely reduced, toxic byproducts accumulate and harm developing immune cells, leaving the body without its usual defenses. Knowing the condition’s history helps explain why early symptoms of ADA deficiency are taken so seriously today and why rapid diagnosis and treatment can be life-saving. Each step—from bedside observations to genetic insight—has shaped today’s care and offers hope for those living with ADA deficiency and their families.